Pinnacle Financial Partners (Georgia)’s Aquestive Therapeutics AQST Stock Holding History

Pinnacle Financial Partners (Georgia)’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.6K	Buy	+10,000	New	+$42.1K	﹤0.01%	1124

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Pinnacle Financial Partners (Georgia)'s AQST Position: Q2 2026 in Review

Pinnacle Financial Partners (Georgia) opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 10,000 shares worth $41.6K. The stake represents ﹤0.01% of the portfolio and ranks #1124 among its holdings.

184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Pinnacle Financial Partners (Georgia) held 10,000 shares of Aquestive Therapeutics worth $41.6K as of Q2 2026.
Aquestive Therapeutics was a new Pinnacle Financial Partners (Georgia) position in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of Pinnacle Financial Partners (Georgia)'s portfolio in Q2 2026, its #1124 holding.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Pinnacle Financial Partners (Georgia)'s 13F filing for Q2 2026, filed 14 Aug 2026.